Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells.

Vet Immunol Immunopathol

Laboratory of Veterinary Molecular Pathology and Therapeutics, Division of Animal Life Science, Institute of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu, Tokyo 183-8509, Japan.

Published: December 2011

Glucocorticoid (GC) administration with or without other chemotherapeutic reagents is a commonly used option in the treatment of mast cell malignancies. However, the responsiveness of mast cell tumors to GC treatment varies in individuals, and the regulatory mechanisms determining the GC sensitivity of malignant mast cells remain unclear. Since the expression of the GC receptor (GR) has been reported to be associated with GC sensitivity in human neoplastic lymphocytes, we attempted to investigate the relationship between GR levels and GC sensitivity by using neoplastic mast cells derived from canine mast cell tumors (MCTs). To elucidate the regulatory mechanisms involved in GC responsiveness, we analyzed various canine MCT cell lines and tissue samples from dogs with MCT. While the proliferation of canine MCT cells was suppressed by the addition of GC to the culture, we found that MCT cells derived from humans and rodents, as well as canine lymphoma cells, responded poorly to GC. However, there were also some variations in responsiveness to GC treatment among canine MCT cell lines used in this study. Using real-time polymerase chain reaction and Western blot analysis, we elucidated the relationship between GR expression and responsiveness to GC in canine MCT cells. Furthermore, to assess the involvement of GR expression in GC sensitivity in vivo, clinical investigations were conducted on dogs with cutaneous MCT. Written informed consent was obtained from owners, and the affected dogs were treated with prednisolone (0.5-2.0 mg kg(-1)day(-1), administered orally) 1 or 2 weeks prior to the surgical removal of the tumors. Tumor volume was measured according to WHO criteria both before and after prednisolone treatment, and the GC sensitivity of each MCT was determined on the basis of the reduction in tumor volume. Of the 15 dogs with MCT, 11 responded to treatment with prednisolone completely or partially, whereas 4 dogs showed no response. Examination of clinical samples obtained by surgical removal revealed that GR expression levels were significantly lower in GC-resistant MCT tissues than in GC-sensitive MCT tissues. Thus, these results strongly indicate that GR expression may contribute to GC sensitivity in canine MCT.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vetimm.2011.08.013DOI Listing

Publication Analysis

Top Keywords

canine mct
20
mast cells
12
mast cell
12
mct
12
mct cells
12
expression levels
8
canine
8
neoplastic mast
8
cell tumors
8
regulatory mechanisms
8

Similar Publications

Exploring canine mast cell tumors: An investigation into demographic characteristics, and grading system analysis from a pathology lab data (2019-2021).

Prev Vet Med

January 2025

DNAtech, Laboratório Veterinário, Lisboa, Portugal; CECAV, Centro de Ciência Animal e Veterinária, Faculdade de Medicina Veterinária, Universidade Lusófona-Centro Universitário de Lisboa, Portugal; CBIOS - Centro de Investigação em Biociências e Tecnologias da Saúde - Universidade Lusófona, Lisboa, Portugal.

Mast cell tumors (MCT) are among the most common neoplasia in dogs, representing up to 21 % of skin tumors. However, etiology and risk factors for its development remain unclear. This study aimed to reduce this knowledge gap by comprehensively analyzing 905 MCT cases diagnosed in Portugal between 2019 and 2021, using descriptive and inferential analyses.

View Article and Find Full Text PDF
Article Synopsis
  • Sentinel lymph node (SLN) mapping is crucial for staging dogs with mast cell tumors (MCTs), but many are referred to oncologists after surgery.
  • A study involving 29 dogs aimed to see if lymphatic drainage patterns change before and after tumor removal by comparing SLN mapping results.
  • The findings showed that surgical intervention did affect lymphatic drainage, with only 46.7% of cases showing complete agreement in SLN identification before and after surgery.
View Article and Find Full Text PDF

Clinical differentiation of cutaneous and subcutaneous mast cell tumors in dogs: A pilot study.

Open Vet J

November 2024

Division of Animal Medical Research, Hassen-kai, 2-27 Onozaki, Saito, Miyazaki 881-0012, Japan.

Background: Canine mast cell tumors (MCT) in the skin are classified into cutaneous MCT (cMCT) and subcutaneous MCT (scMCT) types, which exhibit different clinical behaviors. Although these types have been classified only by histology, preoperative differentiation is important for proper surgical planning.

Aim: To examine the accuracy of differentiating these types based on the gross features before surgery.

View Article and Find Full Text PDF

Mast cell tumours (MCTs) are the most frequent cutaneous neoplasia of the dog, and they have very variable biological behaviour and survival times. Surgery is still the best treatment, and despite the several adjuvant therapies described, many cases are very aggressive and resistant to these treatments making it urgent to find new therapeutic targets. Nowadays, immunotherapy targeting immune checkpoints has been described as a complementary treatment for several human cancers, but it is still very scarcely studied in veterinary medicine.

View Article and Find Full Text PDF

Neoplasia is a common disease in companion animals. Rapid and accurate diagnosis of neoplasia often leads to a better disease outcome. Cytology is an inexpensive and minimally invasive method frequently used to diagnose neoplasia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!